“Less Radical” is the story of Bernie Fisher, the surgeon-scientist who not only revolutionized breast cancer treatment, but also fundamentally changed the way we understand all cancers.
ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a multi-year research collaboration wherein Caris is pairing its genomic, transcriptomic, and proteomic profiling, advanced artificial intelligence and machine learning algorithms with ECOG-ACRIN’s research capabilities.
New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
Flatiron Health announced a milestone of over 1,000 research publications utilizing Flatiron’s electronic health record-derived real world data.
Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.
Less Radical tells the story of surgeon-scientist Bernie Fisher, who revolutionized breast cancer treatment and transformed the way we understand cancer.
The American Cancer Society released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States.
New research on the possibility to kill TNBCs by hijacking signals that normally drive mammary gland involution was released in Nature.
A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center revealed that common breast cancer treatments, including chemotherapy, radiation, and surgery, may accelerate the biological aging process in breast cancer survivors.
FDA approved Itovebi (inavolisib) with palbociclib (Ibrance) and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, human epidermal growth-factor receptor 2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.
